Skip to main content
Edwards Lifesciences Logo

Press releases

newsroom banner image
newsroom banner image
newsroom banner image
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
Edwards Lifesciences to Sell Critical Care to BD
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences Reports Fourth Quarter Results
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023
DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023
EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023
EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT
EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION
EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL
EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022
EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE
EDWARDS ANNOUNCES KEY EVENTS FOR EUROPCR 2022
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2022
EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022
EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021
Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity
Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On July 29, 2021
Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
Edwards Announces Updates From Annual Meeting
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020
Edwards Lifesciences Reports Second Quarter Results
Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2020
Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
Edwards Announces Updates From Annual Meeting
Edwards Lifesciences Announces May 2020 Investor Conference Schedule
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences To Hold Virtual Annual Meeting Of Stockholders
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2020
Edwards SAPIEN 3 Valve Shows Excellent Results At 2 Years
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19
Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference
Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On January 30, 2020
Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On October 23, 2019
Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference
Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2019
Edwards Comments On Updated TAVR National Coverage Determination
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
Edwards Announces Milestones For Transcatheter Mitral Program
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences Completes Acquisition of CASMED
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019
Edwards SAPIEN 3 Valve Proves Superior To Surgery In Partner 3 Trial
Edwards Lifesciences Announces Strategic Investments
Edwards PASCAL Transcatheter System Receives CE Mark
Edwards Lifesciences Enters Into Agreement To Acquire CASMED
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Edwards Comments On U.S. Court Decision
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark
Edwards Comments On German Court Decision
Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018
Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule
Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference
Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
Edwards Lifesciences Reports Second Quarter Results
Edwards Comments On CMS Advisory Panel
Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018
Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR
Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
Edwards Announces Key Events For EuroPCR 2018
Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement
Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy
Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018
Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid
Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe
Edwards' Acumen Hypotension Prediction Index Launches In The U.S.
Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference
Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018
Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Contacts

Investors

Mark Wilterding
(SVP, Investor Relations)

Media

Michael George
Senior Director, Communications

Julie Tracol
Senior Manager, External Communications